Xemed’s fourth generation XeBox polarizer, Hawking, reached two critical milestones this spring. Delivered and installed in 2011 at the Center for In-Vivo Hyperpolarized Gas at the University of Virginia, it completed its fourth year of service on April 25, 2015. Also in April it produced its 1000th liter of Xemed’s Investigational New Drug MagniXene since formal pilot studies and clinical trials began in February 2012. Production volumes of 2 liters to 2.75 liters, typically produced during 20 to 30 minute runs and distributed among three or four dosing bags, were utilized in a wide range of imaging protocols studying a variety of lung disease states. Polarization over the four year period reached maximal values of 59.4% with a median value of 41.4%, measured in the bags.
The hyperpolarized gas human lung imaging team at Robarts Research Institute and University of Western Ontario
Kai Ruppert (UVa), Isabel Dregely (UNH), and Bill Hersman (UNH and Xemed) at the ISMRM Young Investigator Award ceremony
MagniXene® single-breath MR image of a 22 y.o. female healthy volunteer. 0.7L bolus, voxel size =3.1 x 3.1 x 10mm. GRE image acquired using the Siemens Tim Trio at the Center for In-Vivo Hyper-polarized Gas Studies at the University of Virginia.
Image credits: T. A. Altes, G. W. Miller, J. P. Mugler, III, K. Ruppert
Xemed CEO Bill Hersman checks polarizer status
with undergraduate intern Igor Tsentalovich